Physician profile
Matthew P Askin
NPI 1871780528
$12,497.85
in general payments reported to CMS, 2019-2025
46 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $688 · 2021: $1,318 · 2022: $2,519 · 2023: $2,181 · 2024: $2,312 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,814 · Education: $95.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,814.43 |
| Education | $95.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,119.77 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,909.31 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,417.84 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $747.77 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $701.86 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $570.03 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $557.42 | 2019-2024 | |
| Braintree Laboratories, INC. | $475.12 | 2019-2024 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $346.49 | 2019-2025 | Ocaliva |
| Celgene Corporation | $327.40 | 2021-2023 | Zeposia |
| Evoke Pharma, INC. | $307.07 | 2021-2025 | Gimoti |
| Ferring Pharmaceuticals INC. | $303.78 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $260.90 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $246.00 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ardelyx, INC. | $227.51 | 2022-2025 | Ibsrela |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $206.70 | 2023-2025 | Zenpep, Vowst |
| Daiichi Sankyo INC. | $206.37 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $181.69 | 2023-2024 | Idacio |
| Lilly USA, LLC | $158.15 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $145.97 | 2023-2025 | Yuflyma, Vegzelma, Zymfentra |
| Covidien LP | $138.87 | 2019 | |
| Genzyme Corporation | $97.40 | 2022-2024 | |
| Vivus LLC | $76.28 | 2021-2024 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $69.86 | 2020-2023 | |
| Intra-Sana Laboratories | $69.57 | 2022-2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Phathom Pharmaceuticals, INC. | $66.41 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $58.40 | 2021-2023 | Sucraid |
| Madrigal Pharmaceuticals | $49.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $45.97 | 2023-2024 | Renflexis |
| Allergan, INC. | $42.00 | 2019 | |
| Ucb, INC. | $39.76 | 2019 | |
| Novo Nordisk INC | $36.68 | 2025 | Wegovy |
| Medtronic, INC. | $35.00 | 2021-2024 | Endoflip |
| Ipsen Biopharmaceuticals, INC | $34.01 | 2025 | Iqirvo |
| Sandoz INC. | $32.06 | 2023 | Hyrimoz |
| Capsovision, INC. | $31.44 | 2024 | Capsocam Plus |
| Ambu INC. | $23.60 | 2020 | |
| Pentax of America, INC. | $18.31 | 2025 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Exact Sciences Corporation | $17.11 | 2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $16.93 | 2024 | Ingrezza |
| Olympus America INC. | $15.74 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.15 | 2023 | Kristalose |
| W. L. Gore & Associates, INC. | $13.66 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.57 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2023 | Cyltezo |
| Echosens North America, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Askin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.